MATXALEN
VIDAL GARCÍA
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (7)
2018
-
Production of the invasive aspergillosis biomarker bis(methylthio)gliotoxin Within the genus aspergillus: In vitro and in vivo metabolite quantification and genomic analysis
Frontiers in Microbiology, Vol. 9, Núm. JUN
2017
-
Aspergilosis diseminada en un paciente inmunocompetente con bis(metiltio)gliotoxina detectable y galactomanano negativo
Revista Iberoamericana de Micologia, Vol. 34, Núm. 1, pp. 49-52
-
Corrigendum: Identification of rare PB2-D701N mutation from a patient with severe influenza: Contribution of the PB2-D701N mutation to the pathogenicity of human influenza [Front. Microbiol. 8, 575 (2017)] doi: 10.3389/fmicb.2017.00575
Frontiers in Microbiology
-
Identification of rare PB2-D701N mutation from a patient with severe influenza: Contribution of the PB2-D701N mutation to the pathogenicity of human influenza
Frontiers in Microbiology, Vol. 8, Núm. APR
2016
-
Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis
Applied Microbiology and Biotechnology, Vol. 100, Núm. 5, pp. 2327-2334
-
Evaluation of incubation time for dermatophytes cultures
Mycoses, Vol. 59, Núm. 7, pp. 416-418
2015
-
Réplica a «Emergencia de aislados de Mycobacterium tuberculosis complex resistentes a rifampicina y sensibles a isoniazida»
Enfermedades Infecciosas y Microbiologia Clinica